MCID: CLS052
MIFTS: 25

Classic Hairy Cell Leukemia

Categories: Blood diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Classic Hairy Cell Leukemia

MalaCards integrated aliases for Classic Hairy Cell Leukemia:

Name: Classic Hairy Cell Leukemia 59
Leukemic Reticuloendotheliosis 59
Hairy Cell Leukemia 73
Hcl-C 59

Characteristics:

Orphanet epidemiological data:

59
classic hairy cell leukemia
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United States); Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA58017
MESH via Orphanet 45 D007943
UMLS via Orphanet 74 C0023443
ICD10 via Orphanet 34 C91.4

Summaries for Classic Hairy Cell Leukemia

MalaCards based summary : Classic Hairy Cell Leukemia, also known as leukemic reticuloendotheliosis, is related to intrapelvic lymph node leukemic reticuloendotheliosis and leukemia. An important gene associated with Classic Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase). The drugs Cefepime and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells.

Related Diseases for Classic Hairy Cell Leukemia

Diseases related to Classic Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 intrapelvic lymph node leukemic reticuloendotheliosis 12.3
2 leukemia 10.1
3 hairy cell leukemia 10.1

Symptoms & Phenotypes for Classic Hairy Cell Leukemia

Drugs & Therapeutics for Classic Hairy Cell Leukemia

Drugs for Classic Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
2
Ofloxacin Approved Phase 3 82419-36-1 4583
3
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
4
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
5
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
6
Tazobactam Approved Phase 3 89786-04-9 123630
7
Ribavirin Approved Phase 3 36791-04-5 37542
8
Captopril Approved Phase 3 62571-86-2 44093
9
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
10
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
11
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
12
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
13
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
14
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
15
Piperacillin Approved Phase 3 66258-76-2 43672
16
Vancomycin Approved Phase 3 1404-90-6 441141 14969
17
Itraconazole Approved, Investigational Phase 3,Not Applicable 84625-61-6 55283
18
Acyclovir Approved Phase 3 59277-89-3 2022
19
Ondansetron Approved Phase 3,Phase 2,Not Applicable 99614-02-5 4595
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
22
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
23
Dalteparin Approved Phase 3 9005-49-6
24
Palivizumab Approved, Investigational Phase 3 188039-54-5
25
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
26
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
27
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 93-14-1 3516
28
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
29 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
30
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
31
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
32
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
33
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
34
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
35
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37 Analgesics Phase 3,Not Applicable
38 Alkylating Agents Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
39 Renal Agents Phase 3,Phase 1,Phase 2
40 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
41 Cephalosporins Phase 3
42 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
43 Cytochrome P-450 CYP1A2 Inhibitors Phase 3,Not Applicable
44 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
45 Anesthetics Phase 3
46 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
47 Anesthetics, Dissociative Phase 3
48 Anesthetics, General Phase 3
49 Anesthetics, Intravenous Phase 3
50 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 219)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
4 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
5 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
6 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
7 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
8 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
9 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
12 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
15 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
16 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
19 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
20 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
21 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
22 Therapy Optimisation for the Treatment of Hairy Cell Leukemia Recruiting NCT02131753 Phase 2, Phase 3 Cladribine s.c. injection, HCL treatment
23 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Active, not recruiting NCT01829711 Phase 3 moxetumomab pasudotox;IV Bag Protectant for Moxetumomab pasudotox
24 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
25 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
26 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
27 Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab Completed NCT02157181 Phase 2 2CdA +/- Rituximab
28 A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Completed NCT00001567 Phase 2 Roferon-A
29 BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia Completed NCT00074048 Phase 2 BL22
30 Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy Completed NCT00003757 Phase 2
31 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
32 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
33 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
34 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
35 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
36 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
37 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
38 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Completed NCT00867529 Phase 2
39 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
40 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
41 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
42 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
43 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
44 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
45 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
46 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
47 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
48 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
49 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
50 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus

Search NIH Clinical Center for Classic Hairy Cell Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Classic Hairy Cell Leukemia

Anatomical Context for Classic Hairy Cell Leukemia

MalaCards organs/tissues related to Classic Hairy Cell Leukemia:

41
Bone, Bone Marrow, B Cells, T Cells, Liver, Kidney, Colon

Publications for Classic Hairy Cell Leukemia

Articles related to Classic Hairy Cell Leukemia:

# Title Authors Year
1
A rare breed: Wild-type braf and ighv expression in a 29 year old lady with classical hairy cell leukemia. ( 28275540 )
2017
2
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. ( 27903528 )
2016
3
Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630. ( 27013208 )
2016
4
Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. ( 21846972 )
2011
5
Leukemic reticuloendotheliosis: polyclonal surface immunoglobulin on "hairy" cells. ( 417798 )
1978
6
Leukemic reticuloendotheliosis: "hairy cell leukemia," functional and structural features of the abnormal cell in a patient with profound leukocytosis. ( 139955 )
1977
7
Hairy cell leukemia (leukemic reticuloendotheliosis) II. Ultrastructure of the spleen. ( 1260714 )
1976
8
SAczary syndrome. A malignant leukemic reticuloendotheliosis. ( 11851246 )
1965

Variations for Classic Hairy Cell Leukemia

Expression for Classic Hairy Cell Leukemia

Search GEO for disease gene expression data for Classic Hairy Cell Leukemia.

Pathways for Classic Hairy Cell Leukemia

GO Terms for Classic Hairy Cell Leukemia

Sources for Classic Hairy Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....